Minoxidil, drug used to stimulate hair growth has shown to increase elastin deposition in mature human tissue, revealed study published in American Journal of Physiology--Heart and Circulatory Physiology.
Arteries in young, healthy humans and other mammals stretch easily because they contain a protein called elastin. Elastin is produced only during development, however, and is slowly lost with aging. In older people, arteries stiffen as elastin is lost. Stiff arteries contribute to development of high blood pressure and significantly increase the risk of sudden death, stroke, myocardial infarction and cognitive decline. Most treatment strategies in adults aim to reduce high blood pressure. To date, no medication has been shown to increase elastin deposition in mature human tissue.
"We know that genetic conditions, such as Williams-Beuren Syndrome (WS) and supravalvar aortic stenosis (SVAS), lead to abnormally low levels of elastin in developing arteries. As a result, children with WS or SVAS have stiff, narrow arteries and high blood pressure. Like older adults, they are also at increased risk of sudden death and stroke," says co-author Michael "Mish" Shoykhet, M.D., Ph.D.
Shoykhet and a collaborator Beth A. Kozel, M.D., Ph.D., co-designed the study and co-led experiments at Washington University School of Medicine (WUSM). The research team's manuscript was finalized and published after Shoykhet joined Children's National Health System.
Minoxidil is perhaps best known for its potential to improve hair growth when applied to the skin. In a different formulation, minoxidil is sometimes prescribed orally for high blood pressure that has not responded to other medications. Earlier studies have suggested that minoxidil may increase elastin deposition even in mature tissues. The research team conducted the work in experimental models of hypertension and chronic vascular stiffness associated with WS and SVAS. They used ultrasound imaging and magnetic resonance imaging-based arterial spin labeling to gauge minoxidil's impact on vessel mechanics, carotid and cerebral blood flow, and gene expression.
The treatment group in the study received 20 mg of minoxidil per kg daily via their drinking water, from the time they were weaned to 3 months of age. A second treatment group also received minoxidil for three months but was analyzed at 4 months of age, one month after the drug was discontinued. For the gene expression experiments, the preclinical models received minoxidil for two weeks. "Minoxidil not only lowered blood pressure, but also increased arterial diameter and restored carotid and cerebral blood flow. Minoxidil also reduced functional arterial stiffness and increased arterial elastin content," Dr. Shoykhet says. "Equally important, these beneficial changes persisted weeks after the drug was no longer in the bloodstream. The sustained improvements and the increased elastin gene expression suggest that minoxidil treatment may help remodel stiff arteries. Such remodeling may benefit humans whose elastin insufficiency is due to either advanced age or genetic conditions." The study team notes that additional clinical studies are needed to confirm changes in blood flow to end organs in humans and to evaluate blood-flow differences in other key vascular beds impacted by elastin insufficiency, such as in the heart, kidneys, lungs and gut.